Human OATP4C1 were previously shown to transport cardiac glycosides, thyroid hormone, cAMP, and methotrexate [24]. In the rat kidney, Oatp4c1 reduced hypertension, cardiomegaly, and inflammation in the setting of renal failure. This was related to its excretory function in kidney. SLCO4C1 overexpression decreased plasma levels of the uremic toxins, for example, guanidino succinate, and dimethylarginine [74]. Statins, which act as inducers of nuclear aryl hydrocarbon receptors, upregulate SLCO4C1 transcription Inhibitors,research,lifescience,medical [75]. 9.9.

SLCO5A1 This poorly characterized OATP was detected at the mRNA levels in many tissues including heart, skeletal muscle, brain, breast, and blood cells. At the mRNA level it was described in cancers of the liver, bone, and breast. In normal breast tissue, OATP5A1 is located at the cell membrane of epithelial cells lining the Inhibitors,research,lifescience,medical milk ducts. In breast cancer, OATP5A1 loses the membrane localization as immunoreactivity was also visible in the cytoplasm of milk duct cells [73]. Haploinsufficiency of the gene coding for OATP5A1 together with that encoding the heparan sulfate 6-O-endosulfatase 1 acting as a regulator Inhibitors,research,lifescience,medical of numerous growth factors in skeletal embryonic development were found to cause a rare autosomal dominant disorder, the mesomelia-synostoses syndrome. It is characterized by mesomelic limb shortening, acral synostoses, and multiple congenital malformations [76]. 9.10. OATP6A1 OATP6A1

Inhibitors,research,lifescience,medical was originally identified as a cancer/testis (CT) antigen strongly expressed at the mRNA level only in normal testis. Weak expression was seen in spleen, brain, and placenta [22]. Like other CT antigens, OATP6A1 is expressed in a number of cancers (brain, urinary bladder, and lung). Because of its high immunogenic potential,

these CT antigens would be of potential utility as a target for antibody-based therapy for a variety of tumor types [77]. 10. selleck inhibitor Regulation of OATP Expression Altered expression of OATPs after malignant transformation of tissues raises the question about mechanisms involved in the regulation of the expression of these Inhibitors,research,lifescience,medical transporters. Although data on regulatory mechanisms for the expression of OATPs are still rare, regulation of OATP1B1, OATP1B3, OATP2A1, OATP2B1, and OATP4A1 were studied on the transcriptional and posttranscriptional levels. Activation of transcription factors, DNA-dependent Metalloexopeptidase gene silencing, and posttranscriptional modifications are involved in the regulation of their expression [31]. In cancer, these processes may change the expression levels of transporters and/or shift the transporter from the plasma membrane to cytosolic compartments leading to changes in OATP functional properties [6]. Transcriptional regulation by different nuclear receptors plays an important role in the regulation of OATP expression. For example, in breast carcinoma tissue and cancer cell lines, expression of OATP1A2 is closely correlated to the expression of the pregnane-X-receptor (PXR) [78].